Glenmark Pharmaceuticals Share Price
Small Cap | Pharmaceuticals and health care | NSE: GLENMARK | BSE: 532296
₹1,307.45 
-41.55 (-3.08 %)
Last Updated: 21 Feb 2025 04:01 PM
BEARISH
Overview
Open (₹) 1,346.00
High (₹) 1,353.30
Low (₹) 1,291.00
Prev. Close (₹) 1,349.00
Volume 16,806
VWAP (₹) 1,310.38
ROCE (%) 17.01
Industry P/E 43.99
TTM P/E -209.86
P/B Ratio 4.68
Market Cap (₹) Cr.36,707.04
Dividend Yield (%)0.19
EPS (₹) -53.22
ROE-19.14%
Sales Growth (%) -9.06
Profit Growth (%)-479.84
Day Range
1,353.301,353.30
52 Week Range
883.501,830.05
Historical Returns
Returns (6M)
-22.85 %
Returns (1Y)
45.22 %
Returns (3Y)
189.13 %
Returns (5Y)
334.73 %
Returns (6M)
-22.85 %
Returns (1Y)
45.22 %
Returns (3Y)
189.13 %
Returns (5Y)
334.73 %
SWOT Analysis
- Effectively using its capital to generate profits - ROCE improved in the last year
- Company with Low Debt
- Bullish MACD crossover (12,6,9) indicates potential upward price movement.
Technicals
Technical Rating
BEARISHRSI 38.36
MFI 81.38
ATR 60.24
Commodity Channel Index -151.63
ROC125 -22.88
ROC21 -10.15
Williams %R -92.58
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 1,338.70 | 1,377.15 | 1,401.00 | 1,314.85 | 1,276.40 | 1,252.55 | 1,214.10 |
| Week Ago | 1,398.29 | 1,475.22 | 1,519.29 | 1,354.22 | 1,277.29 | 1,233.22 | 1,156.29 |
| Month Ago | 1,526.55 | 1,553.30 | 1,568.70 | 1,511.15 | 1,484.40 | 1,469.00 | 1,442.25 |
EMA & SMA
1307.45
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
20
5 Day 1361.01
9 Day 1389.33
10 Day 1410.51
12 Day 1427.05
14 Day 1422.95
20 Day 1420.95
26 Day 1440.84
50 Day 1494.85
100 Day 1566.15
200 Day 1474.58
Deals & Announcements
Bulk and Block Deals
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| ISHARES INDIA SC MAURITIUS COMPANY | block | Sell | 25 Oct, 2022 | ₹397.90 | 39,265 | BSE |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 25 Oct, 2022 | ₹397.90 | 3,02,621 | BSE |
| ISHARES MSCI INDIA SMALL-CAP ETF | block | Buy | 25 Oct, 2022 | ₹397.90 | 39,265 | BSE |
| ISHARES CORE MSCI EMERGING MARKETS ETF | block | Buy | 25 Oct, 2022 | ₹397.90 | 3,02,621 | BSE |
| ISHARES INDIA SC MAURITIUS COMPANY | block | Sell | 17 Oct, 2022 | ₹390.85 | 39,226 | BSE |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 17 Oct, 2022 | ₹390.85 | 3,02,331 | BSE |
| ISHARES MSCI INDIA SMALL-CAP ETF | block | Buy | 17 Oct, 2022 | ₹390.85 | 39,226 | BSE |
| ISHARES CORE MSCI EMERGING MARKETS ETF | block | Buy | 17 Oct, 2022 | ₹390.85 | 3,02,331 | BSE |
| ISHARES INDIA SC MAURITIUS COMPANY | block | Sell | 11 Oct, 2022 | ₹393.10 | 38,184 | BSE |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 11 Oct, 2022 | ₹393.10 | 2,94,302 | BSE |
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 25 Sept, 2023 | Mr. Praveen D Kurkal | Disposal | ₹852.00 | 1,000 | BSE |
| 25 Sept, 2023 | Mr. Praveen D Kurkal | Disposal | ₹852.00 | 1,000 | BSE |
| 25 Sept, 2023 | Mr. Praveen D Kurkal | Disposal | ₹851.02 | 500 | BSE |
| 24 Nov, 2021 | ROBIN PINTO | Acquisition | ₹490.192 | 250 | BSE |
| 17 Nov, 2021 | SRIDHAR GORTHI | Disposal | ₹535.6833631484794275491949911 | 559 | BSE |
| 29 Sept, 2021 | NEHA SALDANHA | Acquisition | ₹ | 20,000 | BSE |
| 29 Sept, 2021 | RAYNA MARIE SALDANHA | Disposal | ₹ | 10,000 | BSE |
| 29 Sept, 2021 | AISHA LOUISE SALDANHA | Disposal | ₹ | 10,000 | BSE |
| 27 Sept, 2021 | GLENN SALDANHA | Acquisition | ₹513.0152040816326530612244898 | 9,800 | BSE |
| 23 Sept, 2021 | CHERYLANN PINTO | Acquisition | ₹512.8651282051282051282051282 | 1,950 | BSE |
Corporate Actions
| Announcement Date | Subject | Ex - Date | Record Date |
|---|---|---|---|
| 24 May, 2024 | Rs.2.5000 per share(250%)Final Dividend | 13 Sept, 2024 | 01 Jan, 1970 |
| 19 May, 2023 | Rs.2.5000 per share(250%)Final Dividend | 18 Sept, 2023 | 01 Jan, 1970 |
| 30 May, 2022 | Rs.2.5000 per share(250%)Final Dividend | 12 Sept, 2022 | 01 Jan, 1970 |
Announcements
| Date | Source | Detail |
|---|---|---|
| 19 Feb, 2025 | BSE India | Further to our letter dated 5th February, 2025 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR), Regulations 2015, the transcript of the Earnings Call held on Monday, 17th February, 2025 for the third quarter ended December 31, 2024 has been uploaded on the Company''s website. |
| 19 Feb, 2025 | NSE India | Glenmark Pharmaceuticals Limited has informed the Exchange about Transcript |
| 17 Feb, 2025 | BSE India | Details of Analyst / Institutional Investor meeting is enclosed. |
| 17 Feb, 2025 | NSE India | Glenmark Pharmaceuticals Limited has informed the Exchange about Schedule of meet |
| 17 Feb, 2025 | BSE India | Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q3 FY 2024 - 25 Earnings Call held on 17th February, 2025 on the website of the Company. |
| 17 Feb, 2025 | NSE India | Glenmark Pharmaceuticals Limited has informed the Exchange about Link of Recording |
| 14 Feb, 2025 | NSE India | GLENMARK PHARMACEUTICALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent |
| 14 Feb, 2025 | NSE India | Integrated Filing (financials) for the Third Quarter and Nine Months ended December 31,2024 |
| 14 Feb, 2025 | BSE India | Integrated Filing (Financial) for the Third Quarter and Nine Months ended December 31, 2024. |
| 14 Feb, 2025 | BSE India | U.S. FDA inspection at the Company''s Facility at Indore, Madhya Pradesh, India |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 04 Feb, 2025 | 14 Feb, 2025 |
| Quarterly Results | -- | 31 Oct, 2024 | 14 Nov, 2024 |
| Quarterly Results | -- | 01 Aug, 2024 | 14 Aug, 2024 |
| Audited Results & Final Dividend | -- | 15 May, 2024 | 24 May, 2024 |
| Quarterly Results | -- | 31 Jan, 2024 | 14 Feb, 2024 |
| Quarterly Results | -- | 02 Nov, 2023 | 10 Nov, 2023 |
| Quarterly Results | -- | 02 Aug, 2023 | 11 Aug, 2023 |
| Audited Results & Final Dividend | -- | 04 May, 2023 | 19 May, 2023 |
| Quarterly Results | -- | 16 Jan, 2023 | 10 Feb, 2023 |
| Quarterly Results | -- | 03 Nov, 2022 | 11 Nov, 2022 |
Share Holding Pattern
| Owner Name | Dec, 2024 | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
|---|
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is a Public Limited Listed company incorporated on 18/11/1977 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24299MH1977PLC019982 and registration number is 019982. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 7891.12 Cr. and Equity Capital is Rs. 28.22 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
1977
Managing Director
Mr. Glenn Saldanha
NSE Symbol
GLENMARK
Glenmark Pharmaceuticals Management
| Name | Designation |
|---|---|
| Mr. Glenn Saldanha | Chairman & Managing Director |
| Mrs. Cherylann Pinto | Executive Director - Corporate Affairs |
| Mr. V S Mani | Executive Director & Global CFO |
| Mrs. B E Saldanha | Non Executive Director |
| Ms. Saira Ramasastry | Ind. Non-Executive Director |
| Mrs. Vijayalakshmi Iyer | Ind. Non-Executive Director |
| Mr. Rajesh V Desai | Ind. Non-Executive Director |
| Mr. Dipankar Bhattacharjee | Ind. Non-Executive Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| SunPhrmInds | ₹4,46,576.22 | ₹1,643.75  ₹1,669.30(-1.53%) | ₹1,249.800 - ₹1,960.200 |
| Divis Labora | ₹1,56,123.40 | ₹5,757.05 ₹5,978.30(-3.70%) | ₹3,350.050 - ₹6,448.750 |
| Cipla | ₹1,21,675.13 | ₹1,475.75 ₹1,479.70(-0.27%) | ₹1,240.700 - ₹1,702.000 |
| ManKind Phar | ₹1,18,478.90 | ₹2,327.75 ₹2,348.45(-0.88%) | ₹1,910.100 - ₹3,050.000 |
| DrReddysLab | ₹1,15,939.04 | ₹1,151.80 ₹1,170.95(-1.64%) | ₹1,104.690 - ₹1,420.200 |
FAQs on Glenmark Pharmaceuticals
What is the share price of Glenmark Pharmaceuticals?
The share price of Glenmark Pharmaceuticals on 21 Feb, 2025 is ₹ 1,307.45.
What is 52W high and 52W low share price of Glenmark Pharmaceuticals?
The highest and lowest 52W share prices of Glenmark Pharmaceuticals are ₹ 1830.050 and ₹ 766.650
What is the market cap of Glenmark Pharmaceuticals?
The market capitalization of Glenmark Pharmaceuticals as of 21 Feb, 2025 is ₹ 36,707.04 Crores
What is the P/E ratio of Glenmark Pharmaceuticals?
The current P/E ratio of Glenmark Pharmaceuticals as of 21 Feb, 2025 is 43.99
What is the PB ratio of Glenmark Pharmaceuticals?
The PB ratio of Glenmark Pharmaceuticals as of 21 Feb, 2025 is 4.68
Top Gainers
948IHFL26I
IBHFL NCD186
₹845.00
₹705.00 (0.20%)
GREAVESCOT
Greaves
₹281.85
₹234.90 (0.20%)
ASHSI
Ashirwd Stl
₹45.66
₹38.05 (0.20%)
CAPRO
Caprola.Chem
₹62.40
₹52.00 (0.20%)
Top Losers
DHANBANK
Dhanalak.Bnk
₹32.19
₹35.97 (-0.11%)
08MPD
08MPD
₹8.66
₹9.62 (-0.10%)
BALTE
BalurghtTran
₹27.13
₹31.24 (-0.13%)
DARSHANORNA
Darshan Orna
₹4.57
₹5.07 (-0.10%)
Market Indices
Sensex
₹78,699.07
₹78,472.48 (0.00%)